After COVID-19 Vaccine Setbacks, GSK Expands Vir Antibody Pact
Companies’ Respiratory Deal Aims Beyond Coronavirus
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.
